Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer

This study has been completed.

Study NCT00040794 Information provided by Cancer and Leukemia Group B

First Received: July 8, 2002 Last Updated: March 30, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	March 2006
Primary Completion Date:	March 2006 (Final data collection date for primary outcome measure)

Publications:

Ready N, Jänne PA, Bogart J, Dipetrillo T, Garst J, Graziano S, Gu L, Wang X, Green MR, Vokes EE; for the Cancer, Leukemia Group B, Chicago, IL. Chemoradiotherapy and Gefitinib in Stage III Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor and KRAS Mutation Analysis: Cancer and Leukemia Group B (CALEB) 30106, a CALGB-Stratified Phase II Trial. J Thorac Oncol. 2010 Aug 3; [Epub ahead of print]

Ready N, Janne P, Herndon J, et al.: Chemoradiotherapy (CRT) and gefitinib (G) in stage III non-small cell lung cancer (NSCLC): a CALGB stratified phase II trial. [Abstract] J Clin Oncol 24 (Suppl 18): 7046, 375s, 2006.

Ready N, Herndon J, Vokes E, et al.: Initial cohort toxicity evaluation for chemoradiotherapy (CRT) and ZD1839 in stage III non-small cell lung cancer (NSCLC): a CALGB stratified phase II trial. [Abstract] J Clin Oncol 22 (Suppl 14): A-7078, 635s, 2004.